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A functional slow recycling pathway of transferrin is required 
for growth of Chlamydia
Scot P. Ouellette† and Rey A. Carabeo*
Centre for Molecular Microbiology and Infection, Division of Cell and Molecular Biology, Imperial College London, London, UK
An inhibitor of host cell lysophospholipid acyltransferase, an enzyme involved in lipid metabolism 
blocked growth of the obligate intracellular pathogen Chlamydia through its action on the 
transport of transferrin (Tf) via the slow pathway of recycling. A detailed characterization of 
this inhibition revealed that Tf accumulated in vesicles positive for Rab11, with a concomitant 
reduction in the level of Tf found within the transport intermediate Rab4/11 hybrid vesicles. 
The net result was the failure to be recycled to the plasma membrane. In chlamydiae-infected 
cells, the Tf-containing Rab11-positive vesicles were typically found intimately associated with 
the inclusion, and treatment with the inhibitor caused their accumulation, suggesting that the 
timely progression and completion of Tf recycling was necessary for proper chlamydial growth. 
Growth inhibition by the compound could be negated by the simple removal of the Tf-containing 
fraction of the serum, a further indication that accumulation of Tf around the chlamydial inclusion 
was deleterious to the pathogen. Thus, it appears that manipulating the slow recycling pathway 
can have biological consequences for Chlamydia and implies the need to regulate carefully the 
interaction of the inclusion with this host trafficking pathway.
Keywords: Chlamydia, inclusion, slow transferrin recycling pathway, LPAT, iron
the significance to Chlamydia of this association has not been elu-
cidated. Expression of dominant-negative mutants and knockdown 
by RNA interference to interfere with Rab4 function failed to reveal 
any role in chlamydial growth. Recently, the Rab11 GTPase, which 
functions in the slow pathway of Tf recycling, was implicated in 
chlamydial growth but at the level of the Golgi-inclusion interac-
tion (Rejman Lipinski et al., 2009). Without any data that correlates 
inhibition of the transferrin (Tf) recycling pathway with abrogation 
of chlamydial growth, the significance of the localization of these 
vesicles relative to the inclusion remains uncertain.
Transferrin recycling could be divided into two pathways based 
on the kinetics of recycling to the plasma membrane. Approximately 
80–90% of internalized Tf are recycled through the fast/bulk 
pathway within 30 min after internalization; and the recycling Tf 
transits through vesicular compartments positive for Rab5 and/or 
Rab4 GTPases. The remaining population of Tf is retained much 
longer in Rab4 and/or Rab11 positive vesicles within the endocytic 
recycling compartment, and has a longer duration (60–90 min) of 
recycling (Sönnichsen et al., 2000). Given this added complexity 
of Tf recycling, we sought to examine the involvement of both 
pathways in chlamydial growth.
Here, we describe the characterization of a potent inhibitor 
of Tf recycling with regards to its effect on chlamydial growth. A 
screen of a small molecule library identified this compound as a 
potent inhibitor of chlamydial growth. The inhibitor (FR179254) 
targeted both the enzyme acyl-CoA:cholesterol acyltransferase 
(ACAT) and lysophospholipid acyltransferase (LPAT). The dem-
onstrated lack of anti-chlamydial activity of an ACAT-specific 
inhibitor (Sandoz 58-035) or the normal growth of chlamydia in 
ACAT-deficient cell lines indicated that the relevant activity was 
IntroductIon
Chlamydia is a developmentally regulated bacterium that resides 
within its target host cell in a pathogen-defined protective niche 
called an inclusion (Hackstadt, 2000). Chlamydiae do not acquire 
markers of the endocytic pathway but rather appear to intercept 
exocytic traffic as demonstrated by the acquisition of sphingomy-
elin (SM) en route from the trans-Golgi network to the plasma 
membrane (Hackstadt et al., 1996). Furthermore, the chlamydial 
inclusion displays selectivity in its interactions with the exocytic 
pathway by excluding vesicles containing glycoprotein cargo 
(Scidmore et al., 1996a). The significance of SM transport to the 
inclusion is unclear although a recent report by Heuer et al. (2009) 
demonstrated the role of infection-induced Golgi fragmentation 
in chlamydial growth, which correlated the fragmentation of the 
Golgi apparatus with enhanced SM transport to the inclusion. 
However, inhibiting this process had only modest effects on chlamy-
dial growth.
Recent reports from a number of laboratories have begun to 
challenge the limited fusogenicity of the inclusion with vesicu-
lar transport pathways. Several Rab GTPases, including Rab4 and 
Rab11, have been localized to the inclusion membrane, and chlamy-
dial proteins that interact with them have been identified (Rzomp 
et al., 2003, 2006; Cortes et al., 2007). In addition, lipid droplets 
have been found inside chlamydial inclusions (Cocchiaro et al., 
2008), thus the repertoire of organelles and vesicles with which 
Chlamydia interacts is likely to grow.
The observation that Tf-containing vesicles localized around 
the inclusion throughout the chlamydial developmental cycle has 
been repeatedly confirmed (Scidmore et al., 1996b, 2003; van Ooij 
et al., 1997; Al-Younes et al., 1999; Rzomp et al., 2003). However, 
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oleic acid (Sigma) at the time of plating or during reactivation as 
indicated. For recovery experiments, cells were cultured in serum-
free IMDM or IMDM supplemented with serum fractions in the 
presence and absence of FR179254. For all samples, addition of 
inoculum to wells marks the time of infection (t = 0 h). Medium 
was aspirated from the treatment samples of infected cells at 24 h 
p.i., and 1 mL of SPG was added to each well. Cells were scraped and 
collected from each well into a 1.5-mL microfuge tube with three 
glass beads. Samples were vortexed for 45 s and frozen at −80°C. 
Samples were titered for infectivity on fresh cell layers as described 
elsewhere to quantify the number of IFU per well (Ouellette et al., 
2006). At 24 h p.i., cells plated on cover slips were washed with PBS, 
fixed with methanol for 10 min, and carefully washed three times 
with PBS plus 0.025% sodium azide. Infected cultures were stained 
with primary human polyclonal antibody (Ab) against chlamy-
diae and secondary Ab goat anti-human Alexa488 (Invitrogen). 
Immunofluorescence was viewed on an Olympus Fluoview 500 
Laser Scanning Microscope.
Fluorescent MIcroscopy
For all of these assays, HEp-2 cells were plated at 105 cells per well 
on 10 mm cover slips in 24-well tissue culture plates. Cells were 
processed as described after 24 h infection and/or treatment with 
drugs and visualized by confocal microscopy except where indi-
cated. For visualization of lipid droplets, live cells were incubated in 
the presence of 1 μg/mL Bodipy 493/503 (Invitrogen) under normal 
culture conditions for approximately 10 min, rinsed 3× with HBSS, 
and viewed live on a Zeiss Axio Imager.M1 deconvolution micro-
scope. For fluid-phase uptake, live cells were incubated in 50 μg/
mL dextran-647 (10000 MW, fixable; Invitrogen) for 2 h, rinsed 
3× with HBSS, fixed in paraformaldehyde, and imaged. All images 
were acquired using the same exposure settings on the microscope. 
CD63-GFP cells were a kind gift of Dr. Frank Dorsey (Scripps FL). 
Cells were infected and treated as indicated and viewed live 24 h p.i. 
The GFP signal was verified to co-localize with a CD63 Ab (data not 
shown). For SM labeling, control or pre-treated cells were pulse-
labeled with 5 μM BodipyFL-ceramide complexed with defatted 
BSA (dfBSA) (Invitrogen) diluted in IMDM without supplements 
for 30 min at 4°C, washed 3× with HBSS, and chased for 1 h at 37°C 
in back-extraction medium (IMDM + 1% dfBSA) with or without 
drugs as indicated. Cells were then imaged live to visualize inclu-
sions and Golgi. For retrograde trafficking, control cells or cells 
pre-treated with drugs were labeled with 10 μg/mL of Alexa488 
labeled cholera toxin subunit B (CTxB-488; Invitrogen) diluted in 
IMDM medium without any supplements. CTxB-488 was added 
to cells for 1 h at 4°C to pulse-label cell membranes, washed 3× 
with HBSS, and chased by incubating for 1 h at 37°C in medium 
with or without drugs as indicated. Separate samples were fixed in 
paraformaldehyde after the pulse and chase and imaged.
transFectIons
PCR-amplified LAMP-1 sequences were inserted into pEYFP-N1 
(CLONTECH Laboratories, Mountain View, CA, USA) to cre-
ate YFP–LAMP-1 (from Dr. Joel Swanson: Henry et al., 2004). 
Human cDNA to CD4 cloned into pCMV6-XL5 was obtained 
from Origene (Rockville, MD, USA). Rab4-GFP (wild-type and 
dominant-negative) was a kind gift of Dr. Marci Scidmore (Cornell 
indeed LPAT. This was confirmed by the use of the CI-976 com-
pound, which has been characterized to specifically inhibit LPAT 
(Chambers and Brown, 2004). FR179254 targeted the transport 
of Tf through the Rab4/Rab11 double-positive vesicle, which is an 
intermediate transport compartment of the slow recycling path-
way. The net result was the accumulation of Tf in Rab11-positive 
vesicles. This inhibitor-induced Tf accumulation was observed in 
both infected and uninfected cells. Interestingly, we found that the 
removal of Tf-containing fractions from the serum in an attempt 
to prevent accumulation rendered FR179254 ineffective in inhibit-
ing chlamydial growth thus linking abnormal Tf recycling with 
chlamydia development. Furthermore, both Tf accumulation 
and inhibition of chlamydial growth could be mimicked partially 
by overexpressing the dominant-negative mutants of Rab4 and 
Rab11, confirming a role for these Rab GTPases in this process. 
The observed biological link between Tf-containing vesicles and 
the chlamydial inclusion reveals a different picture of the inclu-
sion – a pathogen-defined organelle that is highly interactive with 
host vesicular traffic.
MaterIals and Methods
organIsMs and cell culture
Chlamydia trachomatis L2 EBs were harvested from infected HEp-2 
or HeLa cell cultures at 37°C with 5% CO
2
, purified by discon-
tinuous density gradient centrifugation in Renografin (Bracco 
Diagnostics, Princeton, NJ, USA), and titered for infectivity as meas-
ured by inclusion forming units (IFU). Escherichia coli MG1655 
and the temperature-sensitive ∆plsC (Coli Genetic Stock Center, 
Yale University, New Haven, CT, USA) bacteria were cultured on 
LB plates or broth using standard bacterial culture protocols with 
the mutant being routinely cultured at 30°C. HEp-2, HeLa, COS7, 
CHO, or AC29 (a kind gift of Dr. Chang, Dartmouth University) 
cells were routinely cultivated at 37°C with 5% CO
2
 in IMDM sup-
plemented with 10% fetal bovine serum, 2 mM l-glutamine, and 
10 μg/mL gentamicin (all from Invitrogen, Carlsbad, CA, USA). 
For some experiments, IMDM lacking serum (iIMDM) was used 
in the presence or absence of FR179254 (Calbiochem, La Jolla, CA, 
USA). Serum fractionations were performed sequentially using 50 
or 100 kDa cut-off filters (Millipore) to obtain three fractions rep-
resenting less than 50 kDa, 50–100 kDa, and greater than 100 kDa. 
Fractions were analyzed by standard SDS-PAGE techniques and 
Western blot using a rabbit polyclonal anti-Tf antibody (Abcam, 
Cambridge, UK), and compared to total serum and purified holo-Tf 
(Sigma, St. Louis, MO, USA). Each fraction was normalized for 
volume and subsequently added to iIMDM to a final concentra-
tion of 10%.
QuantIFIcatIon oF IFus FroM InFected cell cultures
HEp-2 cells were plated in 6-well culture plates at a density of 
106 cells per well. In a subset of wells, cells were plated onto glass 
cover slips for immunofluorescence microscopy. Approximately 
18 h later, cells were infected at an MOI of 1 by direct addition 
to each well and left untreated or treated with 20 μM FR179254, 
20 μM U18666a (Calbiochem, La Jolla, CA, USA), 5 μM Triacsin 
C, 50 μM CI-976, or 5 μg/mL Sandoz 58-035 (all from Sigma, St. 
Louis, MO, USA) and infected cells were incubated at 37°C with 
5% CO
2
. For oleic acid experiments, cells were treated with 300 μM 
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the unrelated compound U18666a, which affects a number of 
transport pathways due to its effects on cellular cholesterol home-
ostasis (Higgins et al., 1999), did not have observable effects on 
the inclusion phenotype and only minimal effects on IFU yield. 
This indicated that the inhibition of chlamydial growth may 
be specific to FR179254. The activity of FR179254 was verified 
biochemically by monitoring the levels of unesterified choles-
terol that would result from inhibition of the ACAT enzyme 
by the compound. U18666A did not show inhibitory activity 
toward cholesterol ester synthesis. In testing other ACAT inhibi-
tors, we found the structurally unrelated CI-976, which has been 
reported to inhibit the host cell LPAT (Chambers and Brown, 
2004), to also block chlamydial growth to a similar extent as 
FR179254 (Figure 1A). We concluded, therefore, that FR179254, 
like CI-976, is blocking chlamydial growth through its inhibitory 
action on LPAT.
Fr179254 abrogates chlaMydIal growth Independently oF acat 
actIvIty
We wanted to further exclude host cell ACAT activity in chlamydial 
growth. To examine this, we used two approaches – comparing 
different compounds with established specificity and the use of 
a mutant Chinese hamster ovary (CHO) cell derivative that lacks 
significant ACAT activity (AC29) (Cadigan et al., 1988). Firstly, 
using wild-type CHO cells, we monitored chlamydial growth in 
cells treated with a specific ACAT inhibitor, Sandoz 58-035. This 
compound had no effect on chlamydial growth in contrast to 
FR179254 (Figure 1B). Secondly, the CHO mutant AC29 cells 
remained competent in supporting chlamydial growth. As with 
CHO cells, 58-035 had no effect on chlamydial growth in AC29 cells 
whereas FR179254 severely blocked growth in an ACAT-deficient 
background (Figure 1B). These data give further support to LPAT, 
and not ACAT, as the target of FR179254.
prokaryotIc lpat-lIke enzyMes are not a target For Fr179254
We wanted to disprove that chlamydiae were the target of the LPAT 
inhibitors. This is particularly important because chlamydiae have a 
predicted LPAT-like activity. In E. coli the homologous gene, which 
encodes the LPAT-like activity, is plsC (Zhang and Rock, 2008), and 
mutants of plsC show a growth defect at 42°C (Coleman, 1990). 
Because of the genetic intractability of chlamydiae, we took advan-
tage of the E. coli surrogate experimental system, and assayed the 
effects of our various inhibitors during growth at both 37°C and 
42°C, with the latter mimicking the temperature-sensitive pheno-
type of the ∆plsC mutant. We reasoned that if any of our inhibitors 
were targeting PlsC, then growth should be abrogated at 42°C. We 
cultured E. coli in the presence of 100 μM inhibitor (5× the concen-
tration used to inhibit Chlamydia in vitro) or chloramphenicol as a 
negative control. As a reference, we also monitored the growth of the 
reference ∆plsC mutant at both temperatures. None of the inhibi-
tors we tested, aside from chloramphenicol, was effective at block-
ing E. coli growth at either temperature as judged by OD readings 
and colony forming units (Figure 1C; data not shown). The ∆plsC 
mutant strain showed the expected growth inhibitory phenotype 
at the non-permissive temperature (Figure 1D). Consequently, it 
is unlikely that CI-976 or FR179254 are targeting the prokaryotic 
LPAT homolog.
University: Rzomp et al., 2006). The 2x-FYVE-GFP construct was 
a kind gift of Dr. Jean Celli (Rocky Mountain Labs, NIAID). Rab11 
and Rab5 constructs were obtained from Addgene. One micro-
gram of plasmid was transfected into cells using Fugene 6 (Roche, 
Indianapolis, IN, USA) according to the manufacturer’s direc-
tions. Briefly, control or pre-treated cells were incubated in Opti-
MEM (Invitrogen). One microgram of plasmid DNA was mixed 
with Fugene 6 reagent diluted in Opti-MEM for 30 min and then 
added to cells for 4 h. Medium with or without drugs was added 
to cells, and cultures were incubated overnight. The following day, 
cells were fixed in paraformaldehyde, in some cases after a pulse 
with fluorescently tagged Tf and chased as described. In most 
cases, cells were visualized directly. For CD4, non-permeabilized 
cells were incubated with primary Ab mouse anti-human CD4 
(R&D Systems, Minneapolis, MN, USA) followed by secondary 
goat anti-mouse Alexa488 (Invitrogen). The antibody stained cells 
were then visualized. For the dominant-negative studies, inclusion 
sizes within infected cells were quantified using ImageJ software 
(NIH, Bethesda, MD, USA).
transFerrIn recyclIng
Transferrin conjugated to Alexa488 or Alexa647 (Tf488 or Tf647, 
respectively; Invitrogen) was diluted to 50 μg/mL in IMDM with-
out supplements. Control or pre-treated cells were pulse-labeled 
with 250 μL of Tf488/Tf647 medium for 1 h at 4°C, washed 3× 
with HBSS, and chased by incubating at 37°C in medium with 
or without drugs. At the indicated times, cells were fixed with 4% 
paraformaldehyde overnight at 4°C and viewed by confocal micro-
scopy. Images were taken from multiple fields of view across the 
cover slip using the same exposure settings on the microscope and 
analyzed for total fluorescence intensity within the field of view 
using ImageJ software.
assay For InhIbItIon oF plsc
The plsC mutant phenotype has been characterized by Coleman 
as showing a growth defect at 42°C (Coleman, 1990). Wild-type E. 
coli MG1655 or the ∆plsC strain from a single colony were grown 
overnight at 37°C or 30°C in 5 mL LB broth, respectively. The fol-
lowing day, bacteria were quantified by OD
600
 and diluted in 5 mL 
LB broth to normalize bacterial numbers. Cultures were grown 
for 4 h to ensure mid-log phase growth and then sub-cultured 
again (after normalizing bacterial numbers) in 5 mL broth in the 
presence of 100 μM FR179254 or CI-976, or 50 μg/mL 58-035, or 
34 μg/mL chloramphenicol, or 0.5% DMSO and grown for up to 
8 h at either 37°C/30°C or 42°C. OD600 readings were taken to 
quantify bacterial growth.
results
Fr179254 blocks chlaMydIal growth
We screened a library of low-molecular weight compounds for 
their ability to abolish chlamydial growth. One of the compounds 
identified from the screen was a known inhibitor of the host 
ACAT, FR179254 (Tanaka et al., 1998). A more detailed char-
acterization of its anti-chlamydial activity showed FR179254 at 
20 μM to dramatically inhibit growth of the rapidly growing 
C. trachomatis serovar L2, resulting smaller and less numerous 
inclusions and lower yields of IFU assay (Figure 1A). In contrast, 
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We continued our studies by examining endocytosis by 
 monitoring fluid-phase uptake as measured by Alexa488-dextran 
labeling of endocytic compartments. In untreated cells, strong 
labeling could be seen whereas fluorescence was slightly reduced 
in both the FR179254- and U18666a-treated cells (Figure 2B). The 
similar effects on dextran labeling in the two samples did not cor-
relate with the different effects of the two compounds on chlamy-
dial growth, and thus, fluid-phase uptake could be excluded as the 
targeted process.
We next examined CD63-GFP expressing cells, as a marker for 
late endosome/multivesicular bodies, and LAMP1-transfected cells 
as a marker for the lysosomal compartment. We saw no obvious 
differences in the localization of these markers in FR179254-treated 
or untreated cells, but U18666a induced the accumulation of these 
markers (Figures 2C,D). Contrary to a published study (Beatty, 
2006), we did not see significant CD63 localization in the chlamy-
dial inclusion under any condition examined unless we fixed and 
permeabilized the cells following the methods of Beatty (2006; 
data not shown) for immunofluorescence confocal microscopy: 
our CD63-GFP cells were visualized live. We concluded from these 
experiments that the Chlamydia-relevant transport pathway tar-
geted by FR179254 was unlikely to be the endocytic pathway.
We next assayed the exocytic pathway by monitoring the trans-
port of sphingolipid and glycoprotein cargos to the inclusion and 
plasma membrane, respectively. Many studies have confirmed 
Fr179254 has no dIscernIble eFFect on lIpId droplets, 
endocytIc, exocytIc, or retrograde traFFIckIng In treated 
cells
The chlamydial inclusion is a pathogen-designed organelle with 
limited interaction with host vesicular trafficking pathways. 
However, this image of limited fusogenicity is being challenged by 
a number of reports that describes inclusion interactions with select 
Rab GTPases (Cortes et al., 2007; Rzomp et al., 2003, 2006), which 
are important for vesicular traffic. Displaying a broader range of 
vesicular interactions, especially transport compartments that are 
nutrient-laden, would maximize the potential for robust growth. To 
determine how FR179254 inhibited chlamydial growth, we screened 
a number of intracellular trafficking pathways using fluorescent 
microscopic techniques. In particular we sought a phenotype 
unique to FR179254 by comparing it to untreated and U18666a-
treated cells. To initiate these studies, we assessed lipid droplets in 
untreated and treated cells (Figure 2A). FR179254 treatment, in 
spite of its inhibitory effects on chlamydial growth did not result 
in a change in lipid droplet contents. Furthermore, inclusions were 
present in cells with no detectable lipid droplets. Thus, growth 
inhibition could not be attributed to effects of the compound on 
lipid droplets. A converse experiment was performed in which lipid 
droplets were induced in the presence of FR179254, in an effort 
to rescue chlamydial growth. We observed no such rescue when 
compared to the untreated group (Figure 3).
Figure 1 | Fr179254 blocks chlamydial growth by targeting host cell LPAT 
and not ACAT or bacterial enzymes. (A) FR179254 (FR179) and CI-976 block 
chlamydial growth. Effect of indicated treatments on recovery of inclusion 
forming units (IFUs), a measure for infectious EBs. (B) Chlamydiae grow in the 
absence of ACAT activity. CHO or AC29 cells, a CHO cell mutant which lacks 
ACAT activity, were infected with Chlamydia trachomatis serovar L2 and treated 
with or without FR179254 or the ACAT inhibitor 58-035 and recovery of infectious 
EBs was monitored after 24 h infection. (C) Assay for LPAT inhibition by 
compounds in Escherichia coli. Wild-type E. coli MG1655 were grown in broth for 
4 h in the presence or absence of LPAT and ACAT inhibitors or chloramphenicol 
(Cm) as indicated, and growth was monitored by OD600 at 37°C or 42°C. (D) 
Assay for effect of compounds on ∆plsC mutant. Wild-type or mutant bacteria 
were grown in broth for up to 8 h in the presence or absence of the LPAT inhibitor 
CI-976 or chloramphenicol and growth monitored by OD600 at 30°C or 42°C.
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of fixed cells. The reason for this discrepancy is not known and war-
rants further investigation, but may be explained by the difference 
in methodology vis-à-vis live cell imaging versus observation of 
fixed cells. To verify that trafficking of proteins to the cell membrane 
was not affected by treatment, we monitored CD4 or vesicular sto-
matitis virus G-glycoprotein (VSV-G) transfected, but uninfected 
cells (Figure 2F; data not shown). Transfected cells were pre-treated 
with drugs where indicated and maintained in the presence of drugs 
after transfection. CD4 and VSV-G was visualized on the cell surface 
the observation that SM-containing vesicles are trafficked to the 
 inclusion via a novel route that excludes glycoproteins (Scidmore 
et al., 1996a). To better aid visualization, we delayed treatment with 
drugs until 8 h post-infection to allow for inclusion development. 
When we monitored SM trafficking to the inclusion at 24 h post-
infection in untreated and treated cells by live cell microscopy, we 
observed no defect in labeling of the chlamydiae (Figure 2E). This 
is in contrast to a report by Beatty (2006) that suggested U18666a 
blocked the trafficking of SM to the inclusion during observation 
Figure 2 | Analysis of host cell trafficking pathways during treatment with 
Fr179254. HEp-2 cells were treated as indicated, and trafficking pathways were 
analyzed as described in Section “Materials and Methods.” (A) Lipid droplet (LD) 
visualization with the neutral lipid stain Bodipy 493. (B) Fluid-phase uptake as 
measured by fluorescent dextran. (C) Live cell visualization of multivesicular 
bodies/late endosomes using CD63-GFP expressing HEp-2 cells. (D) Analysis of 
late endosomes/lysosomes in LAMP1-YFP transfected cells. (e) Exocytic 
trafficking as measured by incorporation of fluorescent sphingomyelin (SM) in 
Golgi and chlamydiae. (F) Exocytic trafficking of glycoproteins as measured by 
localization of CD4 on the surface of transfected cells. (g,H) Analysis of 
retrograde trafficking using fluorescently tagged cholera toxin subunit B (CTxB) 
after pulse-chase labeling. Arrows within (C) and (e) indicate inclusions. Note 
the lack of significant staining in (C) (inset) and the presence of staining in 
(e), which is contrast to a published study (Beatty, 2006).
Figure 3 | excess oleic acid fails to reverse the effect of Fr179254. 
Lipid droplets are not the targeted process of FR179254. Cells were 
cultured in normal medium or medium containing excess oleic acid (OA) to 
induce lipid droplets (A) and then infected and treated as indicated with 
either FR179254 or Triacsin C (TrC), a fatty acid synthase and lipid droplet 
inhibitor. (B) Chlamydial growth was assessed at 24 and 48 h post-
infection. One set of samples were reactivated (React) by treating with 
indicated drugs for 24 h, washing three times, and then culturing in the 
presence or absence of excess oleic acid in fresh medium lacking drugs. 
Reactivated samples were collected after 24 h (48 h total culture time). All 
data were normalized to chlamydial growth in untreated cells at 24 h 
post-infection (arbitrarily 100%).
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Tf for 1 h at 4°C to prevent uptake, washed, and shifted to 37°C 
to allow uptake and recycling. Labeling of cells was unaffected by 
treatment. Surprisingly, FR179254 induced a marked retention of 
Tf compared to untreated or U18666a-treated cells that was both 
quantifiable and easily seen in fluorescent images (Figure 4A). We 
also found that Sandoz 58-035 and lipid droplet inhibitors had no 
effect on Tf recycling (data not shown). Thus, it seems that the 
growth inhibitory effects of FR179254 on chlamydiae are due to 
its ability to delay Tf recycling.
To further characterize the effects of FR179254 on Tf recy-
cling, we monitored retention of fluorescent Tf within treated and 
untreated cells over a time course during the chase period. Based 
on the distinct differences in Tf retention of the untreated and 
FR179254-treated samples (Figure 4A), the use of fluorescent Tf 
rather than radioactively labeled ones was deemed sufficient and 
informative. Indeed, we observed that the bulk (approximately 
80%) of endocytosed Tf is rapidly recycled back to the plasma 
membrane within 30 min whereas the remainder is recycled more 
slowly. Up to 30 min chase, there were no significant differences 
between retained fluorescence (Figures 4B,C), marking the initial 
uptake and bulk recycling of Tf through the fast recycling pathway. 
However, after 30 min, we noticed obvious, significant retention 
of labeled Tf within treated cells, which corresponds with the slow 
pathway of Tf recycling (Figures 4B,C). We concluded from these 
without permeabilization of the cells. Here too, we saw no defects in 
labeling and concluded that FR179254 is not affecting the exocytic 
pathway in a way that impacts chlamydial growth.
Another prominent intracellular trafficking pathway is the ret-
rograde transport, which allows for certain endocytosed molecules 
to be diverted to the exocytic pathway where they transit back to 
the ER. We examined the retrograde trafficking of fluorescently 
tagged cholera toxin subunit B (CTxB) in untreated and treated 
cells. After an initial pulse, cells showed good labeling of the mem-
brane, regardless of the conditions used (Figure 2G). Cells were 
then chased in medium for 2 h, fixed, and viewed by confocal 
microscopy. We did not observe any noticeable differences between 
untreated and FR179254-treated cells (Figure 2H). We concluded 
that retrograde transport was unlikely to be the sought-after target 
of FR179254. It appears that FR179254 treatment did not result 
in any qualitative differences in the staining profile and morphol-
ogy of the compartments within the endolysosomal, exocytic, and 
retrograde transport pathways.
Fr179254 Induces a delay In the slow transFerrIn recyclIng 
pathway
Because Tf has been localized to the chlamydial vacuole (Scidmore 
et al., 2003; van Ooij et al., 1997), we examined Tf recycling in 
treated and untreated cells. Cells were pulse-labeled with  fluorescent 
Figure 4 | Slow transferrin recycling is delayed in Fr179254 treated cells. 
HEp-2 cells were treated as indicated, pulsed with fluorescent transferrin, and 
chased for the times shown. (A) Fluorescent micrographs of transferrin 
pulse-chased cells from different conditions at 600× magnification acquired by 
laser scanning confocal microscopy using identical settings. (B) Quantification of 
transferrin fluorescence in treated cells measured over a time course during 
chase. (C) Representative images used for quantification. FR179254 shows no 
effect on transferrin recycling during the early (up to 30′) part of the chase but 
significantly delays recycling during the latter phases. “*” Indicates p < 0.005 
compared to UTD calculated by Student’s t-test. (D) HEp-2 cells were infected 
and treated with different concentrations of FR179254 as indicated and 
processed for immunofluorescence of chlamydial inclusions after 24 h infection. 
Separate samples were treated as indicated and pulse-chased with fluorescent 
transferrin as described previously and imaged at 60′ chase time. Chlamydial 
inclusions were imaged at 400× magnification whereas transferrin staining was 
imaged at 100× magnification using the same settings on the microscope. 
Images were acquired on an epifluorescent microscope. (e) Transferrin is 
recruited to the inclusion periphery and remains there for an extended time 
during FR179254 treatment. Cells were infected and treated with or without 
FR179254 at 12 h post-infection to allow inclusions to develop for easy 
visualization. Cells were then pulse-chased with fluorescent transferrin as 
described at 24 h post-infection.
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hybrid vesicle intermediates that may function in sorting the Tf/
Tf receptor from the endosomal compartments for recycling to 
the plasma membrane via the fast and slow recycling pathways, 
respectively. Cells were transfected with one of three markers either 
individually or in combination with Rab4 (a marker for recycling 
vesicles): Rab5 or 2x-FYVE domain (early endosome markers) or 
Rab11 (late endosome/endocytic recycling compartment). Cells 
were infected and then pulse-chased with Tf and processed for 
confocal microscopy. The number of vesicles co-localizing with 
Tf were quantified.
In untreated cells, Tf-containing vesicles co-localizing with the 
singly transfected markers increase between the end of the Tf pulse 
and 30 min chase (Figure 6A) and decline to “starting” levels by 
60 min chase (Figure 6B). A similar pattern was seen for Tf co-
localizing with the FYVE domain in FR179254-treated cells. In 
contrast, Tf-positive Rab4 vesicles did not decrease after 30 min, and 
Tf-positive Rab11 vesicles accumulated over time (Figures 6A,B), 
consistent with published effects of LPAT inhibition (Chambers 
et al., 2005). To further characterize the compartment in which Tf 
was delayed, we monitored doubly transfected cells for Tf localiza-
tion. There were no differences in Tf localization in Rab5/Rab4 dou-
bly positive compartments between untreated or FR179254-treated 
cells (Figures 6C,D). Curiously, there was a marked decrease in the 
levels of Tf in FR179254-treated Rab4/Rab11 doubly positive com-
partments (Figures 6C,D). However, assessing singly transfected 
Rab11 positive cells within the same cell population revealed that 
this deficit in Tf/Rab4/Rab11 co-localization was compensated by 
an increase in the levels of Tf/Rab11 co-localization compared to 
untreated cells (Figure 6). These data indicated that there was a 
defect in the formation of the Tf-containing Rab4/11 hybrid vesi-
cles. These same observations applied to infected cells, but enu-
meration of vesicles was difficult due to the vesicles around the 
inclusions being less distinct or sometimes appearing fused (data 
not shown). Our observation of Tf transiting through the Rab4/11 
hybrid vesicle on its way to the plasma membrane concurs with the 
model of Tf recycling proposed (Sönnichsen et al., 2000).
co-expressIon oF doMInant-negatIve constructs For rab4 
and rab11 causes retentIon oF transFerrIn and delays 
InclusIon developMent
Previous reports investigating the ability of dominant-negative Rabs 
to inhibit chlamydial growth failed to show any biologically significant 
effects (Rzomp et al., 2006; Rejman Lipinski et al., 2009). Possible 
explanations for this include the compensatory functions provided by 
the wild-type, endogenous proteins and/or the ability of chlamydial 
proteins to selectively interact with them (Rzomp et al., 2006). Given 
the apparent involvement of both Rab4 and Rab11 in the slow recycling 
pathway, we speculated that co-expression of both dominant-negative 
Rab4 and Rab11 may lead to Tf retention and chlamydial growth inhi-
bition. Cells were transfected with both constructs, infected, and fixed 
after 24 h. Tf retention and inclusion sizes were respectively moni-
tored and measured in untransfected, singly transfected, and doubly 
transfected cells within the same population. For the Tf experiment, 
chlamydiae-infected cells were incubated with Alexa647-Tf for a 1-h 
pulse, and chased for 90 min. Figure 7A displays a representative visual 
field with cells harboring chlamydial inclusions (white arrowhead). 
Only cells that expressed both the dominant-negative forms of Rab4 
data that FR179254 specifically affects the transit of Tf through the 
slow recycling pathway while having no effect on the fast recycling 
pathway.
To correlate the delay in Tf recycling with chlamydial growth, 
we monitored chlamydial inclusion development and Tf recycling 
over a dose curve of FR179254. Chlamydial inclusion formation 
was significantly reduced at a concentration of 20 μM, accompa-
nied by the marked retention of fluorescent Tf in parallel sam-
ples (Figure 4D). Lower concentrations failed to show an obvious 
microscopic effect on either chlamydial inclusions development 
or Tf retention, although 10 μM FR179254 inhibited chlamydial 
recovery by approximately 0.5 log (data not shown). An excel-
lent concordance was seen between the effect of FR179254 on 
Tf recycling and chlamydial inclusion formation, supporting the 
notion that interference with the Tf recycling pathway was linked 
to chlamydial growth.
We next examined the effects of FR179254 treatment on the 
subpopulation of Tf that localize around the chlamydial inclusion. 
Would they be refractory to the inhibitor, and thus belong to the 
fast/bulk recycling, or would they be retained similarly as the Tf in 
the slow recycling pathway? We analyzed confocal images of treated 
and untreated infected cells. As others have reported (Al-Younes 
et al., 1999; Rzomp et al., 2006; Scidmore et al., 1996b, 2003; van 
Ooij et al., 1997), we could detect Tf around inclusions at 30 min 
chase time (Figure 4E). By 60 min, most of this staining was absent, 
indicating that the Tf had been recycled away from the inclusion, 
apparently with a kinetics consistent with that of slow recycling. 
Treatment with FR179254 resulted in the retention of Tf around 
the chlamydial inclusion at 30 and 60 min chase times (Figure 4E). 
Based on the susceptibility of this peri-inclusion Tf to FR179254 
treatment, it is very likely that this Tf subpopulation belong to the 
slow pathway of recycling.
MultIple InFluxes oF transFerrIn are delayed by Fr179254 
treatMent
If a pulse of labeled Tf was found to be retained for a longer dura-
tion, it would be logical to assume that under steady state labeling 
or even growth in Tf-rich serum would result in accumulation. 
To investigate further the apparent retention of Tf, we performed 
a double-pulse-chase experiments using Tf conjugated to differ-
ent fluorophores. Untreated and treated cells were initially pulsed 
with Alexa488-Tf, and after 30 min chase time, were pulsed again 
with Alexa647-Tf and chased for a further 60 min. We found that 
each fluorescence label was retained in FR179254-treated cells with 
similar kinetics (see Figure 4) whereas, in untreated or Sandoz 
58-035-treated cells, the fluorescence associated with both Tf pulses 
was lost quite rapidly (Figure 5). These results are consistent with 
a chronic delay of Tf recycling through the slow pathway such that 
each wave of Tf endocytosed by the cell is similarly affected.
Fr179254 treatMent InhIbIts the transport oF transFerrIn to 
the rab4/11 hybrId recyclIng vesIcle
The previously reported effects of CI-976 include delaying the recy-
cling of Tf, and causing the accumulation of Tf in Rab11-positive 
compartments (Chambers et al., 2005). Therefore, we sought to 
determine if the same is true for FR179254. Also, we extended this 
observation by including in the analysis the Rab4/5 and Rab4/11 
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This correlation was also observed in dominant-negative trans-
fection experiments (Figure 7). If Tf accumulation was the pri-
mary cause of growth inhibition of Chlamydia by FR179254, 
we reasoned that omission of Tf from the growth media would 
relieve this inhibition. We monitored chlamydial growth in 
media lacking whole serum or supplemented only with the 
Tf-containing fraction of the serum in FR179254-treated and 
untreated cells. An SDS-PAGE and Western blot analysis of the 
serum fractions (less than 50 kDa, 50–100 kDa, and greater than 
100 kDa) compared to purified Tf or complete serum demon-
strated that the fraction with the greatest amount of Tf was the 
>100 kDa fraction (Figure 8), owing to the tendency of native 
Tf proteins to aggregate during the concentration process. In 
the absence of serum, FR179254 had no effect on chlamydial 
growth, as measured by IFU recovery and visualized by fluores-
cence microscopy of inclusions (Figure 8 and data not shown). 
Consequently, the supplementation of the Tf-containing fraction 
of the serum to the growth media restored the inhibitory effects 
of the compound (red bars in Figure 8 indicate no significant dif-
ference compared to FR). No such restoration of inhibition could 
be observed when other fractions of the serum were used indi-
vidually (purple bars represent a significant difference in growth 
compared to FR treatment; Figure 7). Therefore, we  concluded 
and Rab11 specifically retained Tf that circumscribed the inclusions 
(p < 0.002; chi-square test) whereas expression of Rab4 or Rab11 DN 
only led to a mild retention of Tf fluorescence and untransfected cells 
showed very little Tf retained around the inclusion. Thus, much like 
FR179254, the co-expression of the dominant-negative mutants of 
Rab4 and Rab11 led to relatively higher levels of retained Tf when 
compared to untransfected cells.
As shown previously, singly transfected cells expressing either 
Rab4 or Rab11 dominant-negative GTPases failed to significantly 
reduce chlamydial inclusion size, a correlate for IFU output. Similarly, 
the dominant-negative constructs failed to circumferentially stain the 
inclusion. However, inclusion sizes in cells expressing both dominant-
negative GTPases were significantly reduced albeit not to the same 
extent as for FR179254-treated cells (Figure 7B). In contrast to co-
expression, the lone expression of each dominant-negative mutant 
did not result in a statistically significant decrease in inclusion size, 
suggestive of a synergistic effect of co-expression (Figure 7C).
Fr179254 InhIbItIon oF growth oF Chlamydia Is reversed by 
oMIttIng seruM FroM the MedIuM
We have shown above that FR19254 treatment resulted in the 
significant retention of Tf (Figure 5), and that the Tf retention 
correlated with decreased inclusion development (Figure 4D). 
Figure 5 | Successive waves of internalized transferrin are delayed by 
Fr179254 treatment. Cells were treated as indicated and pulse-chased with 
Tf-488. At 30′ chase, cells were subsequently pulsed with Tf-647. After a total of 
90′ chase time (60′ for Tf-647), cells were fixed and analyzed by confocal 
microscopy. Noticeable accumulation of both fluorescent labels is present in 
FR179254-treated but not Sandoz 58-035-treated or untreated cells.
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Figure 6 | Fr179254 causes a delay in the trafficking of transferrin from 
rab11 compartments to rab4/11 recycling compartments. Transfected cells 
were pulse-chased with fluorescent transferrin (Tf647) as described previously and 
monitored for co-localization with vesicles by confocal microscopy. Representative 
confocal images (A) and quantification (B) of co-localization of transferrin with 
individual markers in singly transfected cells in untreated or FR179254-treated 
conditions. Representative confocal images (C) and quantification (D) of 
co-localization of transferrin with indicated markers in doubly transfected cells.
Figure 7 | Co-expression of dominant-negative constructs of rab4 and 
rab11 gTPases causes retention of Tf and reduces chlamydial inclusion 
growth. Cells were transfected with dominant-negative (DN) constructs of Rab4 
or Rab11 either individually or in conjunction. (A) Transfected cells were 
pulse-chased with fluorescent Tf to monitor Tf retention in these cell types. (B,C) 
Quantification of inclusion size in cells transfected with indicated construct(s) 
with accompanying representative confocal image. * indicates p < 0.001 
compared to UTD by Kruskal–Wallis test.
that the inhibitor activity of FR179254 only manifested in the 
presence of Tf in the growth media. An equally important result 
obtained from this experiment is the normal growth of chlamy-
dia in media lacking serum, but containing the inhibitor, which 
supports our data above (Figures 1 and 4) that the target of the 
compound is not the bacteria.
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dIscussIon
Chlamydia is a medically important pathogen that has proven dif-
ficult to genetically manipulate, thus alternative methods must be 
employed to investigate its biology at a mechanistic level. We used 
a small molecule inhibitor approach to identify chlamydial and 
host processes required for survival of the pathogen, and here, we 
report the identification of an inhibitor of LPAT, which interrupted 
the proper recycling of Tf – specifically via the slow recycling path-
way. In the context of Chlamydia-infected cells, interference of this 
pathway using the small molecule inhibitor suppressed chlamydial 
growth, and thus providing additional insight into the significance 
of the oft-reported localization of Tf around the inclusion.
The chlamydial inclusion lacks markers of the endolysosomal path-
way and is distinct from the phagosomes of other intracellular bacteria, 
which, aside from Coxiella, appear to be arrested within the endolyso-
somal transport pathway (Scott et al., 2003). This unusual character-
istic of the inclusion was reinforced by the reported interaction with 
exocytic Golgi-derived vesicles (Hackstadt et al., 1996; Carabeo et al., 
2003), and the localization to the inclusion of Rab GTPases associated 
with various intracellular trafficking pathways challenged this notion 
of restricted fusogenicity (Rzomp et al., 2003). In this report we demon-
strated the requirement for the proper recycling of Tf through the slow 
recycling pathway in inclusion development and the completion of the 
developmental cycle of Chlamydia. A model is proposed below dem-
onstrating the potential interaction of the chlamydial inclusion with 
the recycling pathway (Figure 9). The preferential interaction with the 







































































































































































Figure 8 | The effect of Fr179254 can be reversed by omission of the 
transferrin-containing fraction of serum from the medium. Infected cells 
were treated with or without FR179254 (FR) and cultured in the presence or 
absence of serum or serum fractions as described in Section “Materials and 
Methods.” IFUs were collected and quantified. Red bars indicate no 
statistically significant difference compared to FR treatment, hence 
restoration of inhibition; whereas purple bars indicate a significant difference 
(p < 0.05 by Student’s t-test). SDS-PAGE analysis and Western blot of serum 
fractions for Tf content compared to complete serum (FBS) and purified, 
commercially available Tf.
Figure 9 | A model for the action of Fr179254 against chlamydiae. 
Transferrin is recycled through two main pathways. For fast recycling, the 
majority of transferrin (∼80%) is endocytosed into a Rab5 positive early 
endosome, which subsequently fuses with Rab4 recycling endosomes for 
transport back to the plasma membrane (PM) in Rab4 vesicles. For slow 
recycling, transferrin (∼20%) is endocytosed into Rab5 early endosomes, 
which mature to Rab11 compartments that then fuse with Rab4 for recycling 
back to the PM. FR179254 delays the fusion of transferrin-containing Rab11 
vesicles with Rab4 recycling vesicles, possibly at the inclusion membrane, 
leading to chlamydial growth abrogation.
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recycling of Tf via the slow pathway. However, this possibility seems 
unlikely as transport of other cargos via the endocytic, retrograde, 
and anterograde pathways seemed unaffected in cells treated with 
the LPAT inhibitor. The apparent specific inhibition of Tf recycling 
by the LPAT inhibitors may be due to unique properties of the 
slow recycling compartment, possibly vesicle tubulation, which is 
critical for recycling, or the localization of critical proteins to the 
slow recycling vesicles. The molecular link between LPAT and Tf 
transport requires further investigation.
How might the slow Tf recycling pathway contribute to chlamy-
dial growth? The lack of obvious siderophore homologs necessitates 
the capture of iron prior to release to the host cytosol, where the 
metal is immediately sequestered by host ferritin. Such a model 
would imply the presence of iron in the slow recycling pathway. 
Indeed, the divalent metal transporter 1 (Dmt1) has been localized 
to the endocytic recycling compartments (Tabuchi et al., 2000), sug-
gesting that iron may be present in these vesicles. The close associa-
tion of the inclusion with these Rab11-positive vesicles would allow 
Chlamydia access to a possible iron source, perhaps by transient 
“kiss-and-run” interaction as has been suggested for phospholipid 
acquisition (Hatch and McClarty, 1998). In the presence of LPAT 
inhibitors, the resulting retention and subsequent accumulation of 
iron-laden compartments around the chlamydial inclusion would 
lead to iron overload and toxicity. Preliminary results indicate that 
chlamydial genes induced under limiting iron availability were, in 
contrast, repressed under conditions of iron overload. Thus, we 
are now investigating the possibility of the slow recycling pathway 
as the source of iron Chlamydia and that the dysregulation of its 
recycling, such as that induced by the LPAT inhibitors results in 
the uncontrolled transfer of potently oxidative Fe2+. Because of the 
deleterious effects of a severely delayed transport of Tf through 
the slow recycling pathway, any interaction the inclusion may have 
with this trafficking compartment would need to be regulated by 
Chlamydia to ensure minimal interference with the recycling of Tf 
to the plasmamembrane.
As with most living organisms, chlamydia absolutely requires 
iron. Iron limitation under in vitro conditions induces aberrant 
growth, growth arrest, and a transcriptional response in chlamy-
dia (Timms et al., 2009; Wehrl et al., 2004; Wyrick, 2010). In vivo, 
interferon-γ, being a potent anti-chlamydial cytokine also mod-
ulates iron acquisition of and metabolism in the host to starve 
intracellular pathogens of this essential metal (Beekhuizen and van 
de Gevel, 2007; Sow et al., 2007; Nairz et al., 2008). Hence, iron 
limitation induced by this cytokine could act in concert with other 
anti-bacterial effectors to effectively eliminate infection. It is tempt-
ing to speculate that the slow recycling compartment could be the 
source of iron that chlamydia utilizes. By interacting directly with 
this pathway, chlamydia bypasses the need to compete with host 
cytosolic ferritins. This mechanism of iron acquisition would be 
especially important for a non-siderophore synthesizing intracel-
lular pathogen.
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The negative effects of LPAT inhibition on the slow recycling 
pathway has been reported previously (Chambers et al., 2005), and 
here, we extend it to Chlamydia-infected cells. We observed that 
the previously reported accumulation of Tf in Rab11 vesicles was 
at the expense of Tf localizing to the Rab4/11 hybrid transport 
intermediate, which Sönnichsen et al. (2000) have proposed to be 
involved in the recycling of Tf to the plasma membrane. This defect 
in the slow recycling pathway could also be observed in infected 
cells, with Tf accumulating around the inclusion. We suspect that 
the Tf accumulation is directly linked to inhibition of chlamydial 
growth because the removal of the Tf-containing fraction from the 
serum alleviated the growth inhibitory effects of FR179254. It is 
possible that chlamydia may have requirements for Tf-independent 
recycling pathway. However, the near-complete restoration of the 
inhibition of chlamydial growth of FR179254 treatment by the 
simple addition of Tf-containing fractions indicate that Tf accumu-
lation contributes significantly to inhibition of chlamydial growth. 
This observation is also important in demonstrating that the target 
of the anti-chlamydial activity of this compound is of host origin; 
otherwise, alleviation of growth inhibition would not have been 
observed in the absence of Tf, while in the continued presence of the 
inhibitor. We could not observe a similar growth inhibition using 
commercially available purified holo-Tf (unpublished observation) 
either due to the difficulty in reaching the Tf concentration level 
found in the serum or the possibly insufficient level of iron loading 
of the commercial preparations of holo-Tf. Further evidence for 
a host target is our demonstration that the co-expression of the 
dominant-negative mutants of Rab4 and Rab11 partially mim-
icked LPAT growth inhibition of chlamydial inclusions, and that the 
prokaryotic LPAT homolog, 1-acylglycerol-3-phosphate acyltrans-
ferase encoded by plsC in E. coli was refractory to the inhibition of 
FR179254. Prokaryotes have an enzyme with predicted LPAT-like 
activity (Zhang and Rock, 2008). This enzyme participates in the 
synthesis of phospholipids from phosphatidic acid. Given the con-
servation of this pathway among prokaryotes and the relatively high 
levels of homology of the enzymes within this biosynthetic path-
way, it is likely the inhibitor would be similarly ineffective toward 
Chlamydia. Furthermore, the PlsC pathway may be dispensable in 
chlamydia, as work by Su et al. (2004) demonstrated that chlamydia 
uses host cell precursors to generate phospholipids, thus circum-
venting any requirement for the Pls system.
How the inhibition of the host cell LPAT links to defects in 
the slow recycling pathway is unknown. There are at least eight 
LPAT isoforms that display differential subcellular localization 
(Shindou and Shimizu, 2009), and Brown and colleagues have 
reported (Chambers and Brown, 2004) that the relevant LPAT 
targeted by CI-976, which we also showed to have similar effects 
with regards to chlamydial infection and Tf transport as FR179254, 
is the Golgi-associated isoform. Because the Golgi apparatus is 
involved in the biogenesis of vesicles in the endosomal compart-
ments, it is possible that interference with the Golgi-associated 
LPAT may affect the Tf-containing Rab11 compartment. However, 
we did not observed defects in the transport to the plasma mem-
brane of protein (CD4 and VSV-G) cargos, or the delivery of SM to 
the chlamydial inclusion. It is tempting to speculate that a drastic 
change induced by LPAT inhibition in the general lipid composi-
tion of intracellular compartments may contribute to the delayed 
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